TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9783966

Group type: EXPERIMENTAL
Intervention: Sonicated albumin enhanced sonography
Number of subjects: 20

Group type: COMPARATOR
Intervention: Voiding cystourethrography
Number of subjects: 20
Study: 7979842

Group type: EXPERIMENTAL
Intervention: Traditional internal medicine clerkship (n=69)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ambulatory medicine and ward medicine (n=38)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ambulatory clerkship
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Overall attitudes towards internal medicine training
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Income potential
Number of subjects: 163
Study: 2781008

Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ioxaglate sodium meglumine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 80
Study: 4987898

Group type: EXPERIMENTAL
Intervention: Mite extract (Dermatophagoides pteronyssinus)
Number of subjects: 28
Study: 31860455

Group type: EXPERIMENTAL
Intervention: Short pulse width (SPW) stimulation (90 μs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Long pulse width (LPW) stimulation (210-450 μs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Crossover groups (SPW and LPW)
Number of subjects: 22
Study: 30606271

Group type: EXPERIMENTAL
Intervention: Lurasidone (20 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 28375559

Group type: EXPERIMENTAL
Intervention: 2-day-stored autologous RBC transfusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 35-day-stored autologous RBC transfusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ex vivo stimulation with LPS and LTA
Number of subjects: 18
Study: 25367835

Group type: EXPERIMENTAL
Intervention: New Beginnings Program (11-week family-focused group preventive intervention)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control condition (literature control condition)
Number of subjects: 161
Study: 23837278

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (10 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg in 10 mL normal saline)
Number of subjects: 60
Study: 21308748

Group type: EXPERIMENTAL
Intervention: Non-trimming of the bladder edges
Number of subjects: 64

Group type: COMPARATOR
Intervention: Trimming of the bladder edges
Number of subjects: 64
Study: 19667972

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 mg alprazolam
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2.0 mg alprazolam
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15863522

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 24
Study: 15605689

Group type: EXPERIMENTAL
Intervention: Doxycin (100 mg)
Number of subjects: 24
Study: 11705752

Group type: EXPERIMENTAL
Intervention: Clonidine (up to 0.3 mg po)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg po)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Clonidine (as low as 0.05 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9717652

Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol 0.5% and latanoprost 0.001% (comb. 10)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol 0.5% and latanoprost 0.005% (comb. 50)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 139

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 139
Study: 1670445

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 6843197

Group type: COMPARATOR
Intervention: Technicians dispensing prescriptions
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Pharmacists dispensing prescriptions
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Pharmacists counseling patients after technicians began dispensing prescriptions
Number of subjects: 900
Study: 31561715

Group type: EXPERIMENTAL
Intervention: Clinically probable laboratory supported ALS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other EEC categories
Number of subjects: 0
Study: 31045589

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/d)
Number of subjects: 134
Study: 28375792

Group type: EXPERIMENTAL
Intervention: Idracemi, 0.3% cortisol phosphate eye drops twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, twice a day
Number of subjects: 40
Study: 28551092

Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 125
Study: 24066735

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Phone call reminders
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: SMS + Phone call reminders
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 224
Study: 21841500

Group type: EXPERIMENTAL
Intervention: Valsartan 640 mg/day
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/day
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/day
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valsartan (all doses)
Number of subjects: 391
Study: 19123865

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 978
Study: 17161118

Group type: EXPERIMENTAL
Intervention: NETA/EE-24 (24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: NETA/EE-24
Number of subjects: 886

Group type: COMPARATOR
Intervention: NETA/EE-21 (21-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Number of subjects: 886
Study: 15079096

Group type: EXPERIMENTAL
Intervention: Stentless aortic bioprosthesis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mechanical aortic valve substitute
Number of subjects: 66
Study: 11342363

Group type: EXPERIMENTAL
Intervention: Cytarabine plus IFN‐alpha
Number of subjects: 810

Group type: COMPARATOR
Intervention: IFN‐alpha alone
Number of subjects: 810
Study: 10188679

Group type: EXPERIMENTAL
Intervention: Petrolatum pretreatment
Number of subjects: 20
Study: 7972620

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Beta-blocking drug (Bisoprolol)
Number of subjects: 32
Study: 2919797

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 20
Study: 168645

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (Premarin) 1.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (Premarin) 2.5 mg
Number of subjects: 0
Study: 30243803

Group type: EXPERIMENTAL
Intervention: LeucoPatch
Number of subjects: 269

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 269
Study: 28915907

Group type: EXPERIMENTAL
Intervention: Mother's recorded voice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stranger's voice
Number of subjects: 66
Study: 26375514

Group type: EXPERIMENTAL
Intervention: CM + CBT (n = 69)
Number of subjects: 116

Group type: COMPARATOR
Intervention: CBT alone (n = 47)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CM + CBT
Number of subjects: 116

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 116
Study: 23051870

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 32
Study: 21681533

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (Group L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (Group H)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study: 17674017

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vitamin A (Control)
Number of subjects: 88
Study: 16549931

Group type: EXPERIMENTAL
Intervention: IL-6 infusion (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion (n = 6)
Number of subjects: 12
Study: 12759270

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (100 micro g in each nostril)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Combination of loratadine (10 mg) and montelukast sodium (10 mg) by mouth once daily
Number of subjects: 63
Study: 10752815

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 9109607

Group type: EXPERIMENTAL
Intervention: Oral iodized oil (100 mg)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 8500312

Group type: EXPERIMENTAL
Intervention: Mail/phone recruitment strategy
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Media recruitment strategy
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Worksite recruitment strategy
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Public site recruitment strategy
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Ongoing monitoring and flexible approach
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Female screenees
Number of subjects: 5887
Study: 3301517

Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide dinitrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (both doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15
Study: 31073885

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet Score
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Adherence Score (MEDAS)
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: Pro-vegetarian dietary pattern
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: Alternate Healthy Eating Index 2010
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: MEDAS and Prime Diet Quality Score (PDQS)
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: High-quality dietary indexes
Number of subjects: 6874
Study: 28927565

Group type: EXPERIMENTAL
Intervention: Stationary Pneumatic Compression Device (SPCD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Portable Pneumatic Compression Device (PPCD)
Number of subjects: 20
Study: 27499030

Group type: EXPERIMENTAL
Intervention: Delay of Events (DoE)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR)
Number of subjects: 1079
Study: 26674353

Group type: EXPERIMENTAL
Intervention: Digene Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: Roche cobas® 4800 HPV Test (COBAS)
Number of subjects: 6172

Group type: COMPARATOR
Intervention: Liquid-based cytology (LBC)
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: HPV 16
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: HPV 18
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: High-grade lesions
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: Low-grade lesions
Number of subjects: 6172

Group type: EXPERIMENTAL
Intervention: HPV 16 and 18
Number of subjects: 6172
Study: 22983689

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nasal dilator adhesive (NDA)
Number of subjects: 12
Study: 22034850

Group type: EXPERIMENTAL
Intervention: 10 week physical education (PE) intervention (2 hours per week of aerobically intense PE)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10 week physical education (PE) intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard PE (control)
Number of subjects: 64
Study: 18269981

Group type: EXPERIMENTAL
Intervention: Upward QRS slope (I(US)) during PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downward QRS slope (I(DS)) during PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency index (rms of bandpass-filtered QRS signal 150-250 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency index (optimum frequency band 125-175 Hz)
Number of subjects: 0
Study: 17147870

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 15206484

Group type: EXPERIMENTAL
Intervention: Inositol (100 mg, twice a day)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 11130524

Group type: EXPERIMENTAL
Intervention: Initial endoscopy
Number of subjects: 422

Group type: COMPARATOR
Intervention: Usual management (control)
Number of subjects: 422
Study: 9360286

Group type: EXPERIMENTAL
Intervention: Moderate threat condition (feedback from a female partner)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High threat condition (feedback from a female partner)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neutral condition (feedback from a female partner)
Number of subjects: 70
Study: 7903508

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alpha‐methyl‐para‐tyrosine and naloxone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Alpha‐methyl‐para‐tyrosine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 3912112

Group type: EXPERIMENTAL
Intervention: 2.5 mg of cyclothiazide daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: 25 mg of hydrochlorthiazide daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Increasing doses of cyclothiazide or hydrochlorthiazide
Number of subjects: 12
Study: 30970404

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine and conventional drugs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo and conventional drugs (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline IL4/IL10 ratio
Number of subjects: 60
Study: 30239842

Group type: EXPERIMENTAL
Intervention: Intravaginal testosterone (IVT) cream (300 μg per dose), self-administered daily for 2 weeks and then thrice weekly for 24 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravaginal testosterone (IVT) cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27696203

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 45 mg/m2 (days 6-8); 15 mg/m2 (days 9-21)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Standard intensive chemotherapy
Number of subjects: 1100
Study: 25102884

Group type: EXPERIMENTAL
Intervention: DICLORAL
Number of subjects: 59

Group type: COMPARATOR
Intervention: Compound Borax Solution
Number of subjects: 59
Study: 21801115

Group type: EXPERIMENTAL
Intervention: Mixture of BoNT‐A (5 U) and BoNT‐B (500 U)
Number of subjects: 14

Group type: COMPARATOR
Intervention: BoNT‐A (10 U) alone
Number of subjects: 14
Study: 19155235

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide (LD IVCY) followed by azathioprine (AZA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: High-dose intravenous cyclophosphamide (HD IVCY) followed by azathioprine (AZA)
Number of subjects: 90
Study: 18071724

Group type: EXPERIMENTAL
Intervention: PD-Feverfew
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15699223

Group type: EXPERIMENTAL
Intervention: High-calorie simple carbohydrate (HC-SC) meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-calorie complex carbohydrate (HC-CC) meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-calorie (LC) meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: All meals (HC-SC, HC-CC, LC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subjective measures of hunger
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin and Leptin
Number of subjects: 20
Study: 12854476

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (60‐80 hrs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PGE1 infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PGE1 infusion
Number of subjects: 20
Study: 10596516

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 25996

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25996
Study: 8605674

Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during therapy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during follow-up
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment at clinical progressive disease
Number of subjects: 204
Study: 1974677

Group type: EXPERIMENTAL
Intervention: Tulobuterol aerosol 400 micrograms tid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Salbutamol aerosol 200 micrograms tid
Number of subjects: 38
Study: 526383

Group type: EXPERIMENTAL
Intervention: Premedication with fentanyl plus atropine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam plus atropine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Etomidate anaesthesia without premedication
Number of subjects: 74
Study: 31111049

Group type: EXPERIMENTAL
Intervention: HPVADL18® (200 mg Echinacea Purpurea and Echinacea Angustifolia) for 4 months after laser therapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: No additional therapy (Control Group B)
Number of subjects: 125
Study: 28218558

Group type: EXPERIMENTAL
Intervention: Three different surgical procedures for primary palatal repair
Number of subjects: 448

Group type: COMPARATOR
Intervention: Common procedure for primary palatal repair
Number of subjects: 448
Study: 25415386

Group type: EXPERIMENTAL
Intervention: All-out pacing
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Athlete-controlled pacing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Computer-controlled pacing
Number of subjects: 15
Study: 26120407

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 µgr every 6 hours until abortion or maximum 48 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin (50 units in 500 cc normal saline, increased to maximum 300 units) with laminaria (6 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study: 21205237

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (3-6 h after symptom onset)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (3-4.5 h after symptom onset)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (4.5-6 h after symptom onset)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator
Number of subjects: 2104
Study: 20108853

Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 16
Study: 16426264

Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan (early administration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan (late administration)
Number of subjects: 20
Study: 15227617

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 221

Group type: COMPARATOR
Intervention: Chloroquine-proguanil
Number of subjects: 221
Study: 11296099

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT) for 8 months (10 sessions)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (evaluation without CT)
Number of subjects: 156
Study: 9247457

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 16
Study: 8500499

Group type: EXPERIMENTAL
Intervention: Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy for 6 to 36 months
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Combination of Oxyprogesterone caproate (OPC) and Tamoxifen administered additionally to surgical and combined therapy
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy in endometrial carcinoma patients
Number of subjects: 540
Study: 3566252

Group type: EXPERIMENTAL
Intervention: Cefoperazone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefoperazone and tobramycin in combination
Number of subjects: 0
Study: 31927126

Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1378
Study: 29914808

Group type: EXPERIMENTAL
Intervention: Intensive supervised pelvic floor muscle training protocol (n=51)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No intervention (control group, n=48)
Number of subjects: 99
Study: 27832671

Group type: EXPERIMENTAL
Intervention: Combined aerobic ‐ resistance training (CT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 32
Study: 24867893

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 30
Study: 22083332

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 120